Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 8213 results

  1. Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI

    In development Reference number: GID-IPG10439 Expected publication date: TBC

    Interventional procedures guidance
    In development

  2. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]

    In development Reference number: GID-TA11203 Expected publication date:  08 April 2026

    Technology appraisal guidance
    In development

  3. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    In development Reference number: GID-TA11440 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  5. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTE10072 Expected publication date:  19 November 2026

    Health technology evaluations
    In development

  6. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  11 August 2026

    Health technology evaluations
    In development

  7. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 19 January 2026.

    Technology appraisal guidance
    In consultation

  8. Suspected Cancer: recognition and referral (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 2 February 2026.

    NICE guideline
    In consultation

  9. Familial Breast Cancer: initial assessment and genetic testing (update)

    In development Reference number: GID-NG10438 Expected publication date:  22 April 2027

    NICE guideline
    In development

  10. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date: TBC

    Interventional procedures guidance
    In development

  11. In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory death

    In development Reference number: GID-IPG10405 Expected publication date: TBC

    Interventional procedures guidance
    In development

  12. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development

  13. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356

    In development Reference number: GID-TA11416 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  14. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448

    In development Reference number: GID-TA11564 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  15. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date:  12 August 2026

    Technology appraisal guidance
    In development